These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 867485)

  • 21. Separation of populations of sensitized lymphoid cells into fractions inhibiting and fractions enhancing syngeneic tumor growth in vivo.
    Small M; Trainin N
    J Immunol; 1976 Jul; 117(1):292-7. PubMed ID: 932428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tryptophan degradation in transplanted tumor cells undergoing rejection.
    Yoshida R; Park SW; Yasui H; Takikawa O
    J Immunol; 1988 Oct; 141(8):2819-23. PubMed ID: 3262668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes.
    Fidler IJ; Bucana C
    Cancer Res; 1977 Nov; 37(11):3945-56. PubMed ID: 908034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
    Cheever MA; Greenberg PD; Fefer A
    Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
    Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
    J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
    Matsumoto T; Himeno K; Mitani M; Mori K; Miake S; Nomoto K
    J Clin Lab Immunol; 1986 Feb; 19(2):83-9. PubMed ID: 3083105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Einstein AB; Fass L; Fefer A
    Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic cell therapy for a murine mammary carcinoma.
    Morecki S; Yacovlev E; Diab A; Slavin S
    Cancer Res; 1998 Sep; 58(17):3891-5. PubMed ID: 9731499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cells from naive mice suppress the in vitro cytotoxic response against endogenous Gross virus-induced tumor cells.
    Tilkin AF; Gomard E; Begue B; Levy JP
    J Immunol; 1984 Jan; 132(1):520-6. PubMed ID: 6228582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In situ lymphoid cells of mouse mammary tumors. III. In vitro stimulation of tumor cell survival by lymphoid cells separated from mammary tumors.
    Blazar BA; Miller FR; Heppner GH
    J Immunol; 1978 Jun; 120(6):1887-91. PubMed ID: 659883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specificity of cytolytic T cells directed against AKR/Gross virus-induced syngeneic leukemias: antibodies directed against H-2K, but not against viral proteins, inhibit lysis.
    Green WR; Nowinski RC; Henney CS
    J Immunol; 1980 Aug; 125(2):647-55. PubMed ID: 6156211
    [No Abstract]   [Full Text] [Related]  

  • 35. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
    Liepins A; Nowicky JW
    Drugs Exp Clin Res; 1996; 22(3-5):103-13. PubMed ID: 8899312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells.
    Kirch ME; Hammerling U
    J Immunol; 1981 Aug; 127(2):805-10. PubMed ID: 6788849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electronic cell volume analysis of growth and rejection of EL-4 ascites tumor cells.
    Zucker RM; Harari J; Finley J; Kambour M
    Am J Vet Res; 1978 Oct; 39(10):1710-2. PubMed ID: 717886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of lymphocytic subpopulations in Friend leukemia virus-induced leukemia.
    Kitagawa M; Matsubara O; Kasuga T
    Cancer Res; 1986 Jun; 46(6):3034-9. PubMed ID: 2870802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Requirement of histocompatible macrophages for the induction of a secondary cytotoxic response to syngeneic tumor cells in vitro.
    Taniyama T; Holden HT
    J Immunol; 1979 Jul; 123(1):43-9. PubMed ID: 312881
    [No Abstract]   [Full Text] [Related]  

  • 40. Expression of antigens coded in murine leukemia viruses on thymocytes of allogeneic donor origin in AKR mice following syngeneic or allogeneic bone marrow transplantation.
    Wustrow TP; Good RA
    Cancer Res; 1985 Dec; 45(12 Pt 1):6428-35. PubMed ID: 2998600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.